The new ruling reverses a jury verdict from four years ago that handed ArcherDx, which no longer exists, $4.7 million in damages.

TBI is a potential new application area for the 8-year-old company, while it continues to commercialize its stroke triage test.

ArteraAI Prostate is authorized for use as a tool to prognosticate long-term outcomes for patients with non-metastatic prostate cancer.

The firm said that it will use the money for working capital and general corporate purposes, and the raise follows a $3.25 million public offering that closed in May.

NEW YORK – The World Health Organization on Monday released an update to its operational handbook on the diagnosis of tuberculosis that provides laboratory personnel, clinicians, ministries of health, ...

Last week, readers were most interested in a story about Diasorin's preparation to enter the point-of-care molecular testing space with a benchtop instrument.

The target device includes a portable instrument and 30-minute, $5 assays requiring only small volumes of whole capillary blood.

The firm's genomics revenues more than doubled year over year, while data and services revenue increased nearly 36 percent.

The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.